Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InViVoCAR1920 mRNA for Relapsed/Refractory B-cell Lymphoma/Leukemia
NCT07321301Phase 2Recruiting
- Sponsor
- Daihong Liu
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of InViVoCAR1920 mRNA in B cell lymphoma, B-cell leukemia (BCL), sponsored by Daihong Liu. Started Sep 2025; status: recruiting.
02
Drugs
InViVoCAR1920 mRNA
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT07321301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321301.